Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: Insights into the antagonism of the hypolipidemic agent Z-guggulsterone-Reference-Cited by-同舟云学术

Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: Insights into the antagonism of the hypolipidemic agent Z-guggulsterone

Published:2014-09 Issue:9 Volume:1844 Page:1684-1693
ISSN:1570-9639
Container-title:Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics

Author:

Yang Liping,Broderick David,Jiang Yuan,Hsu Victor,Maier Claudia S.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Molecular Biology,Biochemistry,Biophysics,Analytical Chemistry

Reference54 articles.

1. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis;Goodwin;Mol. Cell,2000

2. Farnesoid X receptor is essential for normal glucose homeostasis;Ma;J. Clin. Invest.,2006

3. Targeting farnesoid X receptor for liver and metabolic disorders;Fiorucci;Trends Mol. Med.,2007

4. Nucleolus disassembly in mitosis and apoptosis: dynamic redistribution of phosphorylated-c-Myc, fibrillarin and Ki-67;Soldani;Eur. J. Histochem.,2006

5. FXR, a therapeutic target for bile acid and lipid disorders;Westin;Mini Rev. Med. Chem.,2005

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Promising Role of Guggulipid in Rheumatoid Arthritis Management: An In-depth Analysis;Current Rheumatology Reviews;2024-12

2. On the Cholesterol Raising Effect of Coffee Diterpenes Cafestol and 16-O-Methylcafestol: Interaction with Farnesoid X Receptor;International Journal of Molecular Sciences;2024-05-31

3. Conformational restriction shapes the inhibition of a multidrug efflux adaptor protein;Nature Communications;2023-07-18

4. FXR agonists for colorectal and liver cancers, as a stand-alone or in combination therapy;Biochemical Pharmacology;2023-06

5. Multi-model in silico characterization of 3-benzamidobenzoic acid derivatives as partial agonists of Farnesoid X receptor in the management of NAFLD;Computers in Biology and Medicine;2023-05